Risperidone and ethyl pyruvate have protective effects against ketamine-induced cognitive impairments in mice

Eur Rev Med Pharmacol Sci. 2022 Mar;26(5):1708-1716. doi: 10.26355/eurrev_202203_28240.

Abstract

Objective: Ketamine, an N-methyl D-aspartic acid receptor antagonist drug, is reported to produce memory disruptions. The aim of this study was to investigate the protective effects of ethyl pyruvate (EP), a pyruvic acid derivative, and risperidone, an atypical antipsychotic drug, against ketamine-induced cognitive disturbances.

Materials and methods: A passive-avoidance test, a novel object recognition test, and a modified elevated plus maze test were used to assess memory functions. Hippocampal malondialdehyde (MDA) levels were measured to determine the oxidation levels.

Results: Ketamine applications produced memory deficits in all tests and insignificantly increased MDA levels, which were alleviated by risperidone, EP, and combination treatments.

Conclusions: Increased oxidative stress and neurotransmission imbalance can be responsible for ketamine-induced memory disruptions. With its antioxidant effects, EP may be helpful to reduce cognitive impairments related to schizophrenia either alone or in combination with antipsychotics.

MeSH terms

  • Animals
  • Antipsychotic Agents* / adverse effects
  • Cognitive Dysfunction* / chemically induced
  • Cognitive Dysfunction* / drug therapy
  • Cognitive Dysfunction* / prevention & control
  • Ketamine* / pharmacology
  • Mice
  • Pyruvates
  • Risperidone / pharmacology

Substances

  • Antipsychotic Agents
  • Pyruvates
  • ethyl pyruvate
  • Ketamine
  • Risperidone